About Qiagen
Qiagen is a company based in Hilden (Germany) founded in 1984 by Metin Colpan and Jurgen Schumacher was acquired by Thermo Fisher Scientific in March 2020. The company has 5,760 employees as of December 31, 2024. Qiagen has completed 25 acquisitions, including AmniSure, Artus Biotech and Blirt. Qiagen offers products and services including QIAcuityDx, QIAwave Kits, Proteinase K, and TissueLyser III. Qiagen operates in a competitive market with competitors including ArcherDX, Parse Biosciences, Biofidelity, RareCyte and RainDance, among others.
- Headquarter Hilden, Germany
- Employees 5760 as on 31 Dec, 2024
- Founders Metin Colpan, Jurgen Schumacher
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Qiagen India Private Limited
- Date of Incorporation 11 Dec, 2009
- Jurisdiction New Delhi, Delhi, India
-
Annual Revenue
$2.09 B (USD)5.65as on Dec 31, 2025
-
Net Profit
$424.88 M (USD)408.28as on Dec 31, 2025
-
EBITDA
$714.06 M (USD)2.27as on Dec 31, 2025
-
Latest Funding Round
$60.64 K (USD), Grant
Jan 20, 2022
-
Investors
Thermo Fisher Scientific
& 3 more
-
Employee Count
5760
as on Dec 31, 2024
-
Investments & Acquisitions
AmniSure
& 24 more
-
Acquired by
Thermo Fisher Scientific
(Mar 03, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Qiagen
Qiagen is a publicly listed company on the NYSE with ticker symbol QGEN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Qiagen
Qiagen offers a comprehensive portfolio of products and services, including QIAcuityDx, QIAwave Kits, Proteinase K, and TissueLyser III.
Fully automated system for accurate genetic variation detection and quantification
Eco-friendly kits for efficient DNA and RNA sample processing
Enzyme for protein digestion in biological sample preparation
Instrument for effective lysis of challenging biological samples
People of Qiagen
Unlock access to complete
Unlock access to complete
Software Development Team
67 people
Leadership Team
56 people
Sales and Marketing
55 people
Senior Team
47 people
Human Resources and Administration
29 people
Operations Team
17 people
Product Management Team
16 people
Field Team
14 people
Unlock access to complete
Funding Insights of Qiagen
Investors in Qiagen
Qiagen has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include Thermo Fisher Scientific, HHS and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Administers health care and support for military personnel and operations.
|
Locked | Locked | Locked |
Investor details for Qiagen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Qiagen
Qiagen has strategically engaged in corporate development activities, having acquired 25 companies. Notable acquisitions include AmniSure, Artus Biotech and Blirt.
Investment portfolio details for Qiagen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Diagnostic decision support solution for radiologists
|
Locked | Locked | 2017 | Locked | |
|
A DNA sequencing platform for forensic science applications is developed.
|
Locked | Locked | 2017 | Locked | |
|
Genomic data is stored and managed through a cloud-based platform.
|
Locked | Locked | 2012 | Locked |
Complete acquisition details for Qiagen
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Qiagen
Detailed financials for Qiagen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Qiagen Comparisons
Peer comparison for Qiagen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Qiagen
Qiagen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ArcherDX, Parse Biosciences, Biofidelity, RareCyte and RainDance, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
RNA-sequencing transcriptome kits for health data analysis are developed.
|
|
| Locked | Locked | Locked |
Molecular diagnostic assays are developed for target DNA sequence detection.
|
|
| Locked | Locked | Locked |
Developer of technologies for the analysis of rare and single cells in the blood
|
|
| Locked | Locked | Locked |
Developer of nucleic acid detection and quantification systems
|
Detailed competitors of Qiagen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Qiagen
Complete news archive for Qiagen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Qiagen
Qiagen was founded in 1984 and raised its 1st funding round 23 years after it was founded.
Qiagen is headquartered in Hilden, Germany. It is registered at Hilden, North Rhine-westphalia, Germany.
Metin Colpan is the current CEO of Qiagen. They have also founded this company.
As of Dec 31, 2024, the latest employee count at Qiagen is 5,760.
Annual revenue of Qiagen is $2.09B as on Dec 31, 2025.
Qiagen was founded in 1984 in Hilden, Germany, and operates in the biotechnology sector. Molecular diagnostic assays are supported through products that isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. Reagents for PCR, sequencing, detection, automated systems, analytics software, RNAi, epigenetics, and laboratory essentials are provided to research and clinical applications worldwide.
Qiagen's top competitors include Parse Biosciences, ArcherDX and NuProbe.
Qiagen offers QIAcuityDx, QIAwave Kits, Proteinase K, and TissueLyser III.
Yes, Qiagen is publicly traded on NYSE under the ticker symbol QGEN.
Qiagen has made 25 acquisitions, including AmniSure, Artus Biotech, and Blirt.
Qiagen has 4 investors. Key investors include Thermo Fisher Scientific, HHS, European Union, and Military Health.
The ticker symbol of Qiagen is QGEN on NYSE.